Other equities analysts have also recently issued research reports about the company. Cantor Fitzgerald upgraded Humana from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $300.00 to $345.00 in a report on Monday, August 12th. Argus boosted their price target on Humana to $370.00 and gave the stock a “buy” rating in a research report on Wednesday, November 20th. SunTrust Banks upped their price objective on Humana to $350.00 and gave the company a “hold” rating in a research note on Friday, November 15th. They noted that the move was a valuation call. Morgan Stanley reaffirmed a “buy” rating and issued a $360.00 price objective (up from $337.00) on shares of Humana in a research report on Monday, November 18th. Finally, Mizuho started coverage on Humana in a research note on Thursday, October 17th. They set a “buy” rating and a $316.00 target price for the company. One research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $324.82.
Shares of HUM opened at $345.21 on Wednesday. The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.46. The company’s fifty day simple moving average is $315.09 and its 200 day simple moving average is $282.33. Humana has a 1-year low of $225.65 and a 1-year high of $346.80. The company has a market cap of $45.19 billion, a price-to-earnings ratio of 23.73, a PEG ratio of 1.46 and a beta of 0.90.
In other news, insider Timothy Alan Wheatley sold 15,019 shares of Humana stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $345.21, for a total transaction of $5,184,708.99. Also, Director James J. /Ky Obrien sold 2,500 shares of Humana stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $345.21, for a total value of $863,025.00. 0.54% of the stock is currently owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in the stock. Cornerstone Advisors Inc. raised its position in shares of Humana by 9.9% in the third quarter. Cornerstone Advisors Inc. now owns 388 shares of the insurance provider’s stock valued at $99,000 after buying an additional 35 shares in the last quarter. Lindbrook Capital LLC grew its holdings in shares of Humana by 12.0% during the 3rd quarter. Lindbrook Capital LLC now owns 327 shares of the insurance provider’s stock worth $84,000 after purchasing an additional 35 shares in the last quarter. Ballentine Partners LLC grew its holdings in shares of Humana by 2.5% during the 3rd quarter. Ballentine Partners LLC now owns 1,751 shares of the insurance provider’s stock worth $448,000 after purchasing an additional 42 shares in the last quarter. Cim Investment Mangement Inc. grew its holdings in shares of Humana by 4.3% during the 2nd quarter. Cim Investment Mangement Inc. now owns 1,125 shares of the insurance provider’s stock worth $298,000 after purchasing an additional 46 shares in the last quarter. Finally, Savant Capital LLC grew its holdings in shares of Humana by 2.5% during the 2nd quarter. Savant Capital LLC now owns 1,968 shares of the insurance provider’s stock worth $522,000 after purchasing an additional 48 shares in the last quarter. 94.01% of the stock is currently owned by institutional investors and hedge funds.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
See Also: What is a Lock-Up Period?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.